Five immunotherapies with an acceptable side effect/safety profile have been shown to preserve insulin secretion in newly diagnosed T1D: teplizumab and otelixizumab12, rituximab, abatacept, low-dose anti-thymocyte globulin (ATG), and alefacept. The gene discussed is INS; the disease is type 1 diabetes mellitus.